中国血液净化 ›› 2013, Vol. 12 ›› Issue (12): 665-670.doi: 10.3969/j.issn.1671-4091.2013.12.00

• 临床研究 • 上一篇    下一篇

连续性血液滤过治疗心肾综合征病人预后因素分析

李杏1,毛慧娟2   

  1. 1. 南京医科大学
    2. 南京医科大学第一附属医院
  • 收稿日期:2013-08-27 修回日期:2013-09-22 出版日期:2013-12-12 发布日期:2013-12-03
  • 通讯作者: 毛慧娟huijuanmao@126.com E-mail:13851746819@126.com

Prognostic factors in cardiorenal syndrome patients treated with continuous hemofiltration therapy

  • Received:2013-08-27 Revised:2013-09-22 Online:2013-12-12 Published:2013-12-03

摘要: 摘要:目的:了解连续性血液滤过治疗心肾综合征患者的疗效,评估影响其预后的因素,以帮助优化选择获益更多的患者。方法:收集连续性血液滤过治疗的心肾综合征患者59例的临床资料(包括实验室及器械检查结果,血滤参数等),按住院期间生存或死亡分为两组,回顾性分析对住院期间死亡率影响的因素。结果:生存组30人,死亡组29人,血滤前生化指标中血清肌酐、总胆红素、直接胆红素;血常规中白细胞、中性粒细胞比例、血红蛋白、红细胞压积;心脏超声指标中左室舒张末内径、左室收缩末内径、射血分数;血滤开始时的收缩压、平均动脉压以及血滤过程的平均脱水量在两组之间差异具有统计学意义。校正其他因素后,白细胞升高为死亡的危险因素,OR值1.242,95%CI(1.242,1.480);血清肌酐升高为死亡的保护因素,OR值0.994,95%CI(0.989,1.000)。结论:血滤开始时的心功能状况,血滤过程的脱水量与预后密切相关。连续性血液滤过治疗起始时的白细胞计数、血清肌酐与住院期间死亡独立相关。这些指标有助于选择获益更多的适应人群。

关键词: 连续性血液滤过, 心肾综合征, 住院死亡率, 血清肌酐

Abstract: 【Abstract】 Objectives We aimed to investigate the efficacy of continuous hemofiltration in patients with cardiorenal syndrome, to assess the factors affecting their prognosis, and thus to help us optimally select patients who can benefit more from this therapy. Methods Forty-nine patients with cardiorenal syndrome treated with continuous hemofiltration were enrolled in this study. To retrospectively analyze the factors affecting mortality, we collected their clinical data including results from laboratory and instrument examinations, and continuous hemofiltration parameters, and divided them into two groups based on survival or death during hospitalization. Results There were 30 cases in the survival group, and 29 cases in the death group. The results with statistical differences between the survival group and the death group are as follows: (a) biochemical parameters before continuous hemofiltration including serum creatinine (411.123±239.847 vs. 270.393±150.719 μmol/L, P=0.009), serum total bilirubin (10.824±7.859 vs 52.741±111.946 μmol/L, P=0.049), direct bilirubin (4.631±4.057 vs. 27.528±58.753 μmol/L, P =0.041), leukocytes (8.027±4.218 vs. 11.925±6.416 ×109/L, P=0.008), neutrophils (6.530±3.994 vs. 10.015±6.029 ×109/L, P=0.011), hemoglobin (94.13±20.460 vs 108.90±25.753 g/L, P=0.018), and hematocrit (0.2838±0.0555 vs. 0.3247±0.0790, P=0.025); (b) Echocardiographic indicators including left ventricular end-diastolic diameter (47.22±14.103 vs. 62.29±11.470mm, P=0.019), left ventricular end-systolic diameter (31.89±10.386 vs. 46.00±13.051mm, P=0.009), and ejection fraction (60.333±8.231 vs. 50.886±14.580%, P=0.05); (c) Physical examinations at the beginning of continuous hemofiltration including systolic blood pressure (131.47±26.271 vs. 114.28±20.800 mmHg, P=0.007), and mean arterial pressure (90.200±18.020 vs. 80.552±17.357 mmHg, P=0.041); (d) average amount of dehydration in continuous hemofiltration process (2184.167±889.364 vs. 1664.166±775.994ml, P=0.020). After adjustment for other factors, leukocytosis was a risk factor for death (OR=1.242, 95% CI: 1.242, 1.480), and higher serum creatinine was not a risk factor for death (OR=0.994, 95% CI: 0.989, 1.000). Conclusions Cardiac function at the beginning of hemofiltration and the amount of dehydration during hemofiltration process were closely related to the prognosis of cardiorenal syndrome patients. Infection and fluid overload condition at the beginning of continuous hemofiltration were independently associated with the mortality of the disease during hospitalization. These results will help us to select suitable patients who can benefit more from continuous hemofiltration.

Key words: Continuous hemofiltration, Cardiorenal syndrome, Mortality during hospitalization, Serum creatinine